Connect with us

News

New cell therapy for melanoma more effective than existing treatment, trial finds

Avatar Of Rajesh Khanna

Published

on

New Cell Therapy For Melanoma More Effective Than Existing Treatment, Trial Finds
google news

European researchers announced on Saturday that a new treatment for advanced melanoma was more effective than the existing main therapy in a phase 3 clinical trial.

The treatment, which uses a patient’s own immune cells to fight the cancer, has some similarities to another type of treatment that has been shown to be very effective for blood cancers, called CAR-T therapy.

CAR-T therapy involves harvesting a patient’s T cells and modifying them in the lab to turn them into cancer fighters, then injecting the cells back into the patient. Personalized treatment was first shown to be effective a decade ago in some leukemia patients; it is now also used for lymphomas as well as multiple myeloma.

And although it has been explored for solid tumors, which make up the majority of cancers, including melanoma, these tumors present challenges that blood cancers do not. Many blood cancers are homogeneous, which means their cells are uniform. This gives CAR-T therapy a clear target to latch onto and attack. But solid tumors tend to have a number of different cell types that vary widely between cancer types, said Dr. Vincent Lam, an assistant professor of oncology at Johns Hopkins Medicine who specializes in immunotherapies.

This tumor cell heterogeneity makes it difficult to find a practical and universal CAR-T target in solid tumors, said Lam, who was not involved in the new research.

In the melanoma trial, doctors used an approach called TIL therapy. This involves harvesting a patient’s immune cells – in this case, cells called tumour-infiltrating lymphocytes, which are taken from the tumor – but instead of modifying them in the lab as they would with CAR-T therapy, they are simply amplified to produce billions of cells.

These cells are then injected back into the patient’s bloodstream, where they can work to kill the cancer.

“We are expanding them from one million cells to several billion cells,” Dr. John Haanen, a medical oncologist at the Netherlands Cancer Institute, who led the new clinical trial, told NBC News.

Haanen presented the results of the trial – the first of its kind to test TIL therapy against an existing treatment – ​​at the ESMO Congress 2022 meeting in Paris.

“That’s what the field needs to really gain confidence in this emerging therapy. It’s potentially changing practice,” Lam said of the findings.

In the trial, 168 patients with metastatic melanoma were randomly assigned to receive either TIL treatment or the current standard treatment, an immunotherapeutic drug called ipilimumab. Ipilimumab is typically used in people who don’t respond to a first-line treatment called anti-PD-1 therapy; almost all of the patients in the trial did not respond to this treatment.

Patients were followed for a median of nearly three years. Compared to those treated with ipilimumab, patients on TIL treatment experienced a 50% reduction in disease progression and death.

In the TIL group, 20% saw their tumors disappear completely, compared to 7% in the ipilimumab group. Patients are still being followed, but so far the overall median survival time for cancer patients who received TIL treatment was more than two years, compared to just over 1.5 years for those receiving ipilimumab. If a patient is able to go into full remission, the chances of it lasting for years are high, Haanen said.

“For a population that has already failed treatment, this is very good news,” he said.

According to Dr. Michael Davies, chair of melanoma medical oncology at MD Anderson Cancer Center in Houston, TIL therapy has been used in clinical trials to treat melanoma for nearly two decades, but it was the first to compare to an approved drug head to head. The kicker is that it turned out superior.

“This is the first time we’ve achieved such a result with cell therapy immunotherapy for melanoma patients,” said Davies, who serves on the scientific advisory board of Iovance Biotherapeutics, a California-based company that conducts research. phase 2 trial of TIL therapy in patients with melanoma who have failed anti-PD-1 therapy.

Melanoma rates have risen rapidly in the United States over the past 30 years, and although metastatic melanoma, the most severe stage of the disease, in which the cancer has spread to other parts of the body, is relatively rare, it is often fatal.

New Cell Therapy For Melanoma More Effective Than Existing Treatment, Trial Finds

But treatment options for patients with metastatic melanoma have changed dramatically over the past decade, with the development of drugs called checkpoint inhibitors, including ipilimumab and anti-PD-1 treatments. These drugs deploy a person’s natural immune cells in an attack on tumor cells. However, if patients do not respond to these treatments, additional treatment options are few.

Melanoma, however, is particularly suitable for TIL therapy, said Dr. Steve Rosenberg, chief of surgery at the National Cancer Institute in Bethesda, Maryland. Compared to other solid cancers, melanoma tumors have a particularly large number of mutations that are the targets of tumor-infiltrating lymphocytes.

“This approach can work in many types of cancer, but for tumors other than melanoma, selecting the right TIL to use is critical. Melanoma is unique because you can use all TILs without selection,” said Rosenberg, who first proposed TIL therapy in the 1980s.

By itself, the therapy causes very few side effects and none that are long-lasting, Haanen said. However, for it to be effective, TIL therapy must be used in combination with chemotherapy and another drug called interleukin-2, or IL-2, both of which have extensive side effects.

“When you introduce billions of cells, you can’t just add them to the body, you have to make room, and chemotherapy does that by killing the cells,” Haanen said. Then, once the patient is infused with their own lab-grown cells, IL-2 helps the new cells survive.

Rosenberg cautioned that the trial results can only be applied to metastatic melanoma, but added that there is a growing body of research exploring TIL therapy for other solid cancers, including lung and cancer. of the cervix.

TIL therapy is also likely still years away from being approved for use outside of clinical trials, which would open it up to many more patients with metastatic melanoma. Several US-based companies are also investigating TIL therapy.

“There’s more to cell therapy than we first thought,” Haanen said. “It opens up a whole new world of treatment options for the future.”

Follow BNC HEALTH on Twitter & Facebook.

nbcnews

google news
Advertisement

News

Worst apartment ever? | Post Poppin’ with Asia Grace (Video)

Avatar Of Rajesh Khanna

Published

on

Worst Apartment Ever? | Post Poppin' With Asia Grace (Video)
google news

The typical New York landlord doesn’t give a fuck. That’s what TikToker Trina Rose learned the hard way when she encountered rats and cockroaches — and major flooding — in her $3,000-a-month apartment in Brooklyn.

You won’t catch Asia Grace from the Post picking up dead vermin. She called the trendy Williamsburg pad “disgusting” and “uninhabitable”. Worse still, Rose’s “greedy bastard” landlord raised the rent by $800 a month and then put the apartment up for sale for $4,700, she claims.

New York Post

google news
Continue Reading

News

Newcastle confirm deal to sign Garang Kuol from Central Coast Mariners in January as Magpies beat Barcelona against wonderkid who moved to Australia as a refugee

Avatar Of Rajesh Khanna

Published

on

Australian Teenager Kuol Agreed To Sign For Newcastle In January
google news

Newcastle United have announced that they have reached an agreement to sign much-loved teenager Garang Kuol, who will join the Premier League club in January.

The 18-year-old currently plays for Australian side Central Coast Mariners but the Magpies moved quickly to sign him ahead of a queue from top European clubs.

Getty

Australian teenager Kuol agreed to sign for Newcastle in January

Kuol Is Highly Rated And Was Also Wanted By Barcelona

Getty

Kuol is highly rated and was also wanted by Barcelona

Kuol, who recently made his senior international debut for the Socceroos, arrived in the north east on Wednesday to sign the terms, with Newcastle announcing the deal will become official in January 2023 when the transfer window opens.

Speed ​​was key for Eddie Howe, with the Daily Mail reporting that Stuttgart had already made an offer, while Barcelona wanted him on a two-year loan.

He is believed to cost around £300,000 and complete an initial loan spell after joining Newcastle.

Kuol’s family is from Sudan, but fled to Egypt, where Garang was born in 2004.

The family lived in Egypt for a year before moving to Australia as refugees.

Her father, Mawien, and her mother, Antonita, worked as dry cleaners, while Antonita also had a job as a seasonal worker in a fruit factory.

Kuol Made His International Debut Against New Zealand This Week

Getty

Kuol made his international debut against New Zealand this week


And he is now on his way to becoming a Premier League player, as he told his new club’s official website: “It’s unreal.

“As a young boy in Australia, the Premier League is the main thing that everyone watches, but no one really thinks they’ll reach those heights. To be one of those people, to be in the position that I’m in, that’s It’s incredible.

“Now that I’ve signed for Newcastle I want to train hard, play hard, hopefully go to the World Cup and come back here.”

Kuol made his A-League debut for the Central Coast Mariners in April, scoring four goals in his first eight games.

He thrived under the tutelage of Nick Montgomery – the former Sheffield United midfielder.

Kuol made his debut for the Australian national in a friendly against New Zealand during the recent international break.

He was also selected in the 2022 A-League All Stars squad which faced Barcelona in front of over 70,000 spectators in Sydney earlier this year.

And now that he has completed his move to Newcastle, he has followed in the footsteps of his older brother, Alou, who joined Stuttgart last year.

Newcastle United sporting director Dan Ashworth said: “Garang is a very promising young talent and we are delighted that he will continue his development as a Newcastle United player.

“Our philosophy is to invest in our Academy and in exciting young players for the future, as well as players needed to make an immediate impact in the first team.

“We wish Garang well in his remaining matches with the Central Coast Mariners and we hope to see him back on the international stage very soon.”

Watch the World Cup with talkSPORT

Newcastle Confirm Deal To Sign Garang Kuol From Central Coast Mariners In January As Magpies Beat Barcelona Against Wonderkid Who Moved To Australia As A Refugee

At talkSPORT we’re powered by fans, so come join us for the ultimate World Cup fan experience this winter – in the talkSPORT fan zone.

In a huge covered room under the arches of Waterloo in London, we will bring you live screenings of every World Cup game.

There will be Q&A with talkSPORT talent, you’ll be part of our live shows and plenty of food and drink will be on offer too.

Come and have the best World Cup fan experience in London – and enjoy a free pint – with tickets for the England and Wales group stage matches on sale now HERE!

!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’

fbq(‘init’, ‘752905198150451’);
fbq(‘track’, “PageView”);

Sports

google news
Continue Reading

News

Apple shares fall following rare Bank of America downgrade

Avatar Of Rajesh Khanna

Published

on

Apple Shares Fall Following Rare Bank Of America Downgrade
google news

Apple shares fell 4.9% on Thursday after Bank of America analysts gave the stock a rare downgrade.

Analysts lowered their buy rating to neutral, also reducing its price target from $185 to $160 per share. They said they anticipated “weaker consumer demand” over the next year and pointed to macroeconomic challenges.

investment related news

Cnbc Investment Club
3 takeaways from our daily meeting including buying Disney and watching the Club Movers
Small Research Firm Disagrees With Bank Of America Call, Upgrades Apple, Predicts 25% Hike

Cnbc Pro
Small research firm disagrees with Bank of America call, upgrades Apple, predicts 25% hike
Bank Of America Downgrades Apple, Says Consumer Weakness Will End Stock Outperformance

Cnbc Pro
Bank of America downgrades Apple, says consumer weakness will end stock outperformance

The broader market was also negative on Thursday, but Apple’s fall was still greater than that of major indexes like the S&P 500, which fell 2.1% on Thursday.

The downgrade came on the heels of a Bloomberg report on Wednesday that Apple had told some suppliers to scrap plans to ramp up production of its new iPhone 14 after failing to see demand as high as expected. It also put pressure on Apple shares.

A second company, however, disagreed with the BofA rating. Rosenblatt Securities upgraded its rating on Apple from neutral to buy and raised its price target to $189 from $160, implying a 25% upside from current levels. He made the call after his survey of more than 1,000 American adults showed strong demand for even the most expensive new Apple products.

Rosenblatt questioned the production report, writing that there is “a recent history of comparable reports proving misleading when actual numbers are released.”

– CNBC’s Michael Bloom contributed to this report.

Subscribe to CNBC on YouTube.

WATCH: Apple shares fall as BofA downgrades stocks

cnbc

google news
Continue Reading

News

US Army needs more ammo

Avatar Of Rajesh Khanna

Published

on

Us Army Needs More Ammo
google news

Vladimir Putin claims to annex parts of Ukraine his troops currently occupy, while threatening to use nuclear weapons if war does not go his way, so now is not the time for Western democracies to waver. . The Biden administration deserves credit for announcing $1.1 billion in additional security aid this week, but buried in the details is a warning about America’s ability to sustain a long war.

The Pentagon has announced “the start of a procurement process” that will eventually supply Ukraine with more multi-mission radars, anti-piloted aerial systems, tactical vehicles that tow weapons and other equipment . The United States will also purchase 18 high-mobility artillery rocket systems, known as Himars, to complement the 16 that Ukraine is currently using to excellent effect on the battlefield, especially at depots. ammunition and Russian logistics lines.

wsj

google news
Continue Reading

News

‘She-Hulk’ release schedule: When is episode 8 coming to Disney Plus?

Avatar Of Rajesh Khanna

Published

on

'She-Hulk' Release Schedule: When Is Episode 8 Coming To Disney Plus?
google news

The latest Marvel series to discover Disney+ stars the incredible Tatiana Maslany like She-Hulk. She-Hulk: Lawyer is a half-hour scripted comedy about Jennifer Walters, the Hulk’s equally green cousin.

The first season consists of nine episodes. Six are directed by Kat Coiro and the other three by Anu Valia, with Jessica Gao as head writer. Originally, She-Hulk was set to pick up the Ms. Marvel release spot on Wednesdays, but episodes will now arrive every Thursday. Clear your schedules for the light series.

Exact She-Hulk episode release dates and times

Here are the exact episode release times.

The first sensational trailer

After a teasing which did indeed tease us (by not showing She-Hulk’s face), Marvel released the first official trailer on May 17. This time we see what She-Hulk will look like in her stunning green glory.

She-Hulk also stars Mark Ruffalo, Benedict Wong and Tim Roth, who starred as the main antagonist in 2008’s The Incredible Hulk. casting.

CNET

google news
Continue Reading

News

The roof of a commercial truck flies and causes an accident in Lebanon

Avatar Of Rajesh Khanna

Published

on

The Roof Of A Commercial Truck Flies And Causes An Accident In Lebanon
google news

A commercial driver in Lebanon literally flipped his lid on Tuesday after the roof of his van truck blew off on Interstate 89. New Hampshire State Police were called to the scene of an accident near the exit 17 earlier this week after a driver hit a large piece of metal while driving. Further investigation revealed that the piece of metal was the roof of a large utility vehicle that had flown off a truck. The truck driver only stopped briefly after the incident before driving off, but the victim was able to provide police with a description and license plate number. Officers from the Canaan Police Department then observed the suspect vehicle driving down Route 4 in Canaan and were able to arrest the driver. Police determined that the driver, Ross King, 40, of Houston, hit a bridge in New York City the day before and continued driving despite extensive roof damage and other safety violations. King was arrested for driving under the influence of narcotics and later released ahead of his court appearance in November. He was also taken out of service for 24 hours due to his condition and for having a fake logbook. The truck was inspected and taken out of service due to its condition. No one was injured in the incident.

A commercial driver in Lebanon literally flipped his lid on Tuesday after the roof of his van truck exploded on Interstate 89.

New Hampshire State Police were called to the scene of an accident near Exit 17 earlier this week after a driver hit a large piece of metal while driving. Further investigation revealed that the piece of metal was the roof of a large utility vehicle that had come off a truck.

The truck driver only stopped briefly after the incident before driving off, but the victim was able to provide police with a description and license plate number.

Officers from the Canaan Police Department then observed the suspect vehicle driving down Route 4 in Canaan and were able to arrest the driver.

Police determined that the driver, Ross King, 40, of Houston, hit a bridge in New York City the day before and continued driving despite extensive roof damage and other safety violations.

King was arrested for driving under the influence of narcotics and later released ahead of his court appearance in November. He was also taken out of service for 24 hours due to his condition and for having a fake logbook.

The truck was inspected and taken out of service due to its condition.

No one was injured in the incident.

Cnn

google news
Continue Reading

Trending